Genmab Soars as Cancer Drug Impresses in a Late-Stage Trial

Genmab A/S shares rose after the company announced that its experimental ovarian cancer treatment met primary endpoints in a late-stage trial. The Danish drugmaker did not immediately disclose specific trial results or analyst estimates in available reports. Genmab develops monoclonal antibody treatments for cancer and other serious diseases.

• Bloomberg — Genmab Soars as Cancer Drug Impresses in a Late-Stage Trial

Next story